Literature DB >> 1842182

Merkel cell carcinoma. Prognosis and management.

A Yiengpruksawan1, D G Coit, H T Thaler, C Urmacher, W K Knapper.   

Abstract

Seventy patients with Merkel cell carcinoma were treated at Memorial Sloan-kettering Cancer Center between 1969 and 1989. The overall estimated 5-year survival rate was 64%. Factors predictive of improved survival included head and neck site and negative lymph nodes at presentation. Local recurrence was seen in 18 patients (26%) and did not correlate with patient-, tumor-, or treatment-related variables. Nine patients with local recurrence (50%) were free of disease following aggressive reoperation. Regional nodes were involved at some point during the course of the disease in forty-six patients (66%). Regional lymph node involvement was apparent within 2 years of diagnosis in 40 (87%) of 46 patients in whom it occurred. Systemic disease was nearly uniformly preceded by the appearance of nodal metastases and was uniformly fatal regardless of subsequent therapy. This suggests an orderly "cascade" pattern of spread for this tumor, in which elective regional lymph node dissection may be justified. Our recommendations for treatment include a wide excision of the primary tumor and either elective or early therapeutic regional node dissection. The role of adjuvant radiotherapy or chemotherapy remains unproven.

Entities:  

Mesh:

Year:  1991        PMID: 1842182     DOI: 10.1001/archsurg.1991.01410360088014

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  54 in total

1.  Brain metastasis of Merkel cell carcinoma.

Authors:  M Turgut
Journal:  Neurosurg Rev       Date:  2002-03       Impact factor: 3.042

2.  Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.

Authors:  Bianca D Lemos; Barry E Storer; Jayasri G Iyer; Jerri Linn Phillips; Christopher K Bichakjian; L Christine Fang; Timothy M Johnson; Nanette J Liegeois-Kwon; Clark C Otley; Kelly G Paulson; Merrick I Ross; Siegrid S Yu; Nathalie C Zeitouni; David R Byrd; Vernon K Sondak; Jeffrey E Gershenwald; Arthur J Sober; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2010-06-19       Impact factor: 11.527

3.  Primary neuroendocrine (merkel cell) carcinoma of the anterior skull base.

Authors:  C Matula; K Roessler; M Burian; H Schuster; S Trattnig; J A Hainfellner; H Budka
Journal:  Skull Base Surg       Date:  1997

Review 4.  Impact of sentinel lymph node biopsy in patients with Merkel cell carcinoma: results of a prospective study and review of the literature.

Authors:  Sofiane Maza; Uwe Trefzer; Maja Hofmann; Silke Schneider; Christiane Voit; Thomas Krössin; Andreas Zander; Heike Audring; Wolfram Sterry; Dieter L Munz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-24       Impact factor: 9.236

Review 5.  Merkel cell carcinoma of skin: diagnosis and management strategies.

Authors:  Michael Poulsen
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Pituitary metastasis of Merkel cell carcinoma.

Authors:  Alberto Feletti; Elisabetta Marton; Sabrina Rossi; Fabio Canal; Pierluigi Longatti; Domenico Billeci
Journal:  J Neurooncol       Date:  2009-10-06       Impact factor: 4.130

Review 7.  Focus on Merkel cell carcinoma: diagnosis and staging.

Authors:  Marion Grandhaye; Pedro Gondim Teixeira; Philippe Henrot; Olivier Morel; Francois Sirveaux; Jean-Luc Verhaeghe; Alain Blum
Journal:  Skeletal Radiol       Date:  2015-01-30       Impact factor: 2.199

8.  Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status.

Authors:  Aleodor A Andea; Raj Patel; Selvarangan Ponnazhagan; Sanjay Kumar; Patricia DeVilliers; Darshana Jhala; Isam E Eltoum; Gene P Siegal
Journal:  Hum Pathol       Date:  2010-07-01       Impact factor: 3.466

9.  Prognostic significance of lymph node ratio in patients with Merkel cell carcinoma.

Authors:  Alexandra Fochtmann; Georg Haymerle; Rainer Kunstfeld; Johannes Pammer; Matthaeus Ch Grasl; Boban M Erovic
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-07       Impact factor: 2.503

10.  A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331).

Authors:  Wolfram E Samlowski; James Moon; Ralph J Tuthill; Michael C Heinrich; Naomi S Balzer-Haas; Stuart A Merl; Ronald C DeConti; John A Thompson; Merle T Witter; Lawrence E Flaherty; Vernon K Sondak
Journal:  Am J Clin Oncol       Date:  2010-10       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.